This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457
by Zacks Equity Research
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Will Ironwood Suffer From Dependence on Linzess' Progress?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
by Kinjel Shah
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck
by Zacks Equity Research
The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.
Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up
by Zacks Equity Research
Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.
Clovis Posts Data on Rubraca Study for Pancreatic Cancer
by Zacks Equity Research
Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Advaxis Up on Positive Early-Stage Immunotherapy Study Data
by Zacks Equity Research
Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
AstraZeneca's Selumetinib Gets Breakthrough Therapy Status
by Zacks Equity Research
AstraZeneca's (AZN) MEK 1/2 inhibitor, selumetinib gets Breakthrough Therapy designation for the treatment of paediatric patients with inoperable NF1-related PN.
AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) focuses on the NDA for Fotivda in the United States for the treatment of advanced or metastatic RCC.
AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo
by Kinjel Shah
AstraZeneca (AZN) signs a collaboration deal, potentially costing $6.9 billion, with Japan's Daiichi Sankyo to develop/commercialize a promising cancer treatment.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals
by Zacks Equity Research
AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.
Calithera (CALA) Initiates Phase I/II Study of Telaglenastat
by Zacks Equity Research
Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.
Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
by Zacks Equity Research
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.
Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million
by Zacks Equity Research
Bayer (BAYRY) and partner Johnson & Johnson settle about 25,000 claims over blood thinner, Xarelto for $775 million.
AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone
Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Las Vegas Sands (LVS), Phillips 66 (PSX) and AstraZeneca (AZN).
The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores
PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
by Zacks Equity Research
PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.